https://www.businessline.global/rhizen-pharmaceuticals-ag-announces-that-its-partnered-asset-umbralisib-ukoniq-has-received-us-fda-accelerated-approval-for-adult-patients-with-relapsed-or-refractory-mzl-fl/press-release/
Rhizen Pharmaceuticals AG Announces That Its Partnered Asset, Umbralisib (UKONIQâ„¢), Has Received US FDA Accelerated Approval for Adult Patients With Relapsed or Refractory MZL & FL